Jaidip Chakravartti, MD
Cardiovascular Disease · Scarborough, MENPI 1639432966
Payments from drug & device makers
What this record shows
This record is dominated by grants: $5,000 of the $8,167 with a category attached, or 61.2%. Medtronic accounts for 61.2% of it on its own, with 5 other manufacturers making up the rest. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $742.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$3K
- Boston Scientific$273
- Abiomed$126
- Cardiovascular Systems Inc.$104
- Siemens Medical Solutions USA, Inc.$32
What the payments were for
- Consulting fees$1,00012%
- Speaking & faculty fees$1,50018%
- Grants$5,00061%
- Food & beverage$6678%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $5,000 |
| Abbott | 4 | $2,633 |
| Boston Scientific | 2 | $273 |
| Abiomed | 2 | $126 |
| Cardiovascular Systems Inc. | 1 | $104 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$2,620
- OPTICROSS$273
- Diamondback Coronary$104
How this compares
$8,167 in reported general payments places this provider in the 95th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 27 | $1,291 |
| Ezetimibe | 44 | $929 |
| Metoprolol Succinate | 60 | $703 |
| Bumetanide | 12 | $693 |
| Atorvastatin Calcium | 56 | $577 |
| Amlodipine Besylate | 21 | $303 |
| Furosemide | 27 | $173 |
| Metoprolol Tartrate | 12 | $143 |
| ClopidogrelClopidogrel Bisulfate | 21 | $139 |
| Losartan Potassium | 11 | $123 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $122 |
| Carvedilol | 11 | $118 |
| Lisinopril | 24 | $69 |
| Spironolactone | 16 | $38 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Scarborough
- Marco DiazScarborough$6K
- Shiva AnnamalaiScarborough$4K
- Anuj MedirattaScarborough$835
- Daniel ShpilskyScarborough$633
- Jeffrey RosenblattScarborough$551
- Christopher ValenteScarborough$428
- Andrew KeibelScarborough$384
- Abraham AbernethyScarborough$354
- Cameron DonaldsonScarborough$234
- David BurkeyScarborough$197
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.